表紙
市場調査レポート

Edison Pharmaceuticals, Inc. : 製品パイプライン分析

Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321978
出版日 ページ情報 英文 25 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Edison Pharmaceuticals, Inc. : 製品パイプライン分析 Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月12日 ページ情報: 英文 25 Pages
概要

Edison Pharmaceuticals, Inc.は米国に本社を置くファーマシューティカル企業で、ミトコンドリア機能障害やその他神経疾患を対象にレドックス制御異常治療薬の創薬および開発を行っています。

当レポートでは、Edison Pharmaceuticals, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Edison Pharmaceuticals, Inc. の基本情報

  • Edison Pharmaceuticals, Inc. の概要
  • 主要情報
  • 企業情報

Edison Pharmaceuticals, Inc. :R&Dの概要

  • 主な治療範囲

Edison Pharmaceuticals, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Edison Pharmaceuticals, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 開発段階が不明のパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Edison Pharmaceuticals, Inc. :薬剤プロファイル

  • vatiquinone
  • EPI-589
  • Small Molecules for Metabolic and CNS Disorders

Edison Pharmaceuticals, Inc. :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Edison Pharmaceuticals, Inc. :最新のパイプライン情報

Edison Pharmaceuticals, Inc. :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07514CDB

Summary

Global Markets Direct's, 'Edison Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Edison Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Edison Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Edison Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Edison Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Edison Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Edison Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Edison Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Edison Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Edison Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Edison Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Edison Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Edison Pharmaceuticals, Inc. Snapshot
    • Edison Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Edison Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Edison Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Edison Pharmaceuticals, Inc. - Pipeline Products Glance
    • Edison Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Edison Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Edison Pharmaceuticals, Inc. - Drug Profiles
    • vatiquinone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPI-589
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Metabolic and CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Edison Pharmaceuticals, Inc. - Pipeline Analysis
  • Edison Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Edison Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Edison Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Edison Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Edison Pharmaceuticals, Inc., Key Information
  • Edison Pharmaceuticals, Inc., Key Facts
  • Edison Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Edison Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Edison Pharmaceuticals, Inc. - Phase II, 2015
  • Edison Pharmaceuticals, Inc. - Phase I, 2015
  • Edison Pharmaceuticals, Inc. - Preclinical, 2015
  • Edison Pharmaceuticals, Inc. - Discovery, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Edison Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Edison Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Edison Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top